157 related articles for article (PubMed ID: 28407731)
1. Segmentum: a tool for copy number analysis of cancer genomes.
Afyounian E; Annala M; Nykter M
BMC Bioinformatics; 2017 Apr; 18(1):215. PubMed ID: 28407731
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
[TBL] [Abstract][Full Text] [Related]
3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH.
de Biase D; Acquaviva G; Visani M; Marucci G; De Leo A; Maloberti T; Sanza V; Di Oto E; Franceschi E; Mura A; Ragazzi M; Serra S; Froio E; Bisagni A; Brandes AA; Pession A; Tallini G
J Mol Diagn; 2021 Sep; 23(9):1185-1194. PubMed ID: 34186176
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide Copy Number Variation Detection Using NGS: Data Analysis and Interpretation.
Shen W; Szankasi P; Durtschi J; Kelley TW; Xu X
Methods Mol Biol; 2019; 1908():113-124. PubMed ID: 30649724
[TBL] [Abstract][Full Text] [Related]
6. Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma.
Nuechterlein N; Shapiro LG; Holland EC; Cimino PJ
Acta Neuropathol Commun; 2021 Dec; 9(1):191. PubMed ID: 34863298
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
8. Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue-a glioma-driven study.
Van der Eecken K; Van der Linden M; Raman L; Creytens D; Dedeurwaerdere F; De Winne K; Ferdinande L; Lammens M; Menten B; Rottiers I; Van Gaever B; Van den Broecke C; Van de Vijver K; Van Roy N; Verbeke S; Van Dorpe J
Virchows Arch; 2022 Mar; 480(3):677-686. PubMed ID: 35034191
[TBL] [Abstract][Full Text] [Related]
9. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
10. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.
Favero F; Joshi T; Marquard AM; Birkbak NJ; Krzystanek M; Li Q; Szallasi Z; Eklund AC
Ann Oncol; 2015 Jan; 26(1):64-70. PubMed ID: 25319062
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma.
Marescalco MS; Capizzi C; Condorelli DF; Barresi V
J Oral Pathol Med; 2014 Jan; 43(1):20-7. PubMed ID: 23750501
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
13. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.
Shen R; Seshan VE
Nucleic Acids Res; 2016 Sep; 44(16):e131. PubMed ID: 27270079
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.
Dubbink HJ; Atmodimedjo PN; van Marion R; Krol NMG; Riegman PHJ; Kros JM; van den Bent MJ; Dinjens WNM
J Mol Diagn; 2016 Sep; 18(5):775-786. PubMed ID: 27461031
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Tesileanu CMS; van den Bent MJ; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Sabedot TS; Hoogstrate Y; von Deimling A; de Heer I; van IJcken WFJ; Brouwer RWW; Aldape K; Jenkins RB; Dubbink HJ; Kros JM; Wesseling P; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; Noushmehr H; French PJ
Neuro Oncol; 2021 Sep; 23(9):1547-1559. PubMed ID: 33914057
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic evidence for subtypes of oligoastrocytomas.
Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
[TBL] [Abstract][Full Text] [Related]
17. CLImAT: accurate detection of copy number alteration and loss of heterozygosity in impure and aneuploid tumor samples using whole-genome sequencing data.
Yu Z; Liu Y; Shen Y; Wang M; Li A
Bioinformatics; 2014 Sep; 30(18):2576-83. PubMed ID: 24845652
[TBL] [Abstract][Full Text] [Related]
18. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
Baumgarten P; Harter PN; Tönjes M; Capper D; Blank AE; Sahm F; von Deimling A; Kolluru V; Schwamb B; Rabenhorst U; Starzetz T; Kögel D; Rieker RJ; Plate KH; Ohgaki H; Radlwimmer B; Zörnig M; Mittelbronn M
Neuropathol Appl Neurobiol; 2014 Feb; 40(2):205-16. PubMed ID: 24117486
[TBL] [Abstract][Full Text] [Related]
19. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.
Idbaih A; Marie Y; Lucchesi C; Pierron G; Manié E; Raynal V; Mosseri V; Hoang-Xuan K; Kujas M; Brito I; Mokhtari K; Sanson M; Barillot E; Aurias A; Delattre JY; Delattre O
Int J Cancer; 2008 Apr; 122(8):1778-86. PubMed ID: 18076069
[TBL] [Abstract][Full Text] [Related]
20. CloneCNA: detecting subclonal somatic copy number alterations in heterogeneous tumor samples from whole-exome sequencing data.
Yu Z; Li A; Wang M
BMC Bioinformatics; 2016 Aug; 17():310. PubMed ID: 27538789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
